A selective and potent GluR5 kainate receptor agonist (Ki = 4.3 nM), inactive at GluR6 (Ki > 1 mM) and only weakly active at AMPA receptors (GluR1-4) and the kainate receptors KA-2 and GluR7 (Ki values of 6 - 14 μM). Also available as part of the Kainate Receptor Tocriset™.
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 228.25. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.38 mL||21.91 mL||43.81 mL|
|5 mM||0.88 mL||4.38 mL||8.76 mL|
|10 mM||0.44 mL||2.19 mL||4.38 mL|
|50 mM||0.09 mL||0.44 mL||0.88 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Clarke et al (1997) A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission. Nature 389 599 PMID: 9335499
Matzen et al (1997) AMPA receptor agonists: synthesis, protolytic properties, and pharmacology of 3-isothiazole bioisasteres of glutamic acid. J.Med.Chem. 40 520 PMID: 9046343
Moldrich et al (1999) Excitotoxic injury profiles of low-affinity kainate receptor agonists in neuronal cultures. Eur.J.Pharmacol. 378 R1 PMID: 10478637
If you know of a relevant reference for ATPA, please let us know.
View Related Products by Product Action
Keywords: Selective potent GluR5 agonists Glutamate Kainate Receptors iGlur Ionotropic Kainate Receptors
5 Citations for ATPA
Citations are publications that use Tocris products. Selected citations for ATPA include:
Randall et al (2011) Fast oscillatory activity induced by kainate receptor activation in the rat basolateral amygdala in vitro. Eur J Neurosci 33 914 PMID: 21255131
Dargan et al (2009) ACET is a highly potent and specific kainate receptor antagonist: characterisation and effects on hippocampal mossy fibre function. Neuropharmacology 56 121 PMID: 18789344
Xu et al (2006) Presynaptic regulation of the inhibitory transmission by GluR5-containing kainate receptors in spinal substantia gelatinosa. Mol Pain 2 29 PMID: 16948848
Liu et al (2004) Astrocyte-mediated activation of neuronal kainate receptors. Mol Pain 101 3172 PMID: 14766987
Song et al (2015) Minocycline does not affect long-term potentiation in the anterior cingulate cortex of normal adult mice. Front Pediatr 11 25 PMID: 25933605
Do you know of a great paper that uses ATPA from Tocris? If so please let us know.
Literature in this Area
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.